Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

  • End date
    Oct 30, 2024
  • participants needed
  • sponsor
    The First Affiliated Hospital of Dalian Medical University
Updated on 4 October 2022


This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.


Chronic kidney disease is a common disease that affects health seriously. In some regions of China, the morbidity of this kind of disease is as high as 10.8%. Primary glomerulopathy is one of the pathogenesis of chronic kidney disease, which occupied 50%-60%. However, at present, there is still a lack of effective means for the treatment of primary glomerulonephritis in CKD stage 3. Huaiqihuang Granule is a kind of Chinese herbal medicine compound preparation, Previous researches showed that Huaiqihuang has a comprehensive effect on primary glomerulonephritis. In this study, there were about 40 first-class hospitals participating in. We planned to enroll 466 participants, who will be randomly divided into the Huaiqihuang Granule group (experimental group) and the Valsartan group (control group). All participants will take medication for 48 weeks, and investigators will follow up participates at weeks 0, 8,16, 24, 32, 40, 48.

Condition Renal Insufficiency, Chronic
Treatment Huaiqihuang granules, Valsartan capsule
Clinical Study IdentifierNCT04263922
SponsorThe First Affiliated Hospital of Dalian Medical University
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Diagnosed as primary glomerulonephritis by renal biopsy
Male or female, 18≤age≤65
Blood pressure can be effectively controlled at or below 140/90mmHg
30mL/(min.1.73m2)≤ eGFR<60mL/(min.1.73m2)
24-hour urine protein ration ≤ 2.0g/24h
The participants must be capable of understanding and comply with the protocol and sign a written informed consent document

Exclusion Criteria

Diagnosed as secondary glomerulonephritis
Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period
Blood pressure < 90/60 mmHg
Serum potassium > 5.5 mmol/L
Serum albumin < 30g/L
Unilateral or bilateral renal artery stenosis
Pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period
Having comorbidities that affect the progression of primary glomerulonephritis (including but not limited to Malignant tumors, Systemic autoimmune diseases, Liver cirrhosis, Diabetes, and Gout)
Allergic to the Huaiqihuang Granule or valsartan
Participating in another clinical trial
Investigators do not think it suitable for a participant to join this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note